Page 155 - 2020_01-Haematologica-web

The vascular niche in chronic myeloid leukemia
A
B
C
D
E
F
G
Figure 7. SCL/TAL1 influences outcome in human chronic myeloid leukemia. (A, B) Delta Ct values for CD44 and SCL/TAL1 in peripheral blood leukocytes of healthy individuals (n=10) (A) or patients with chronic myeloid leukemia (CML) (n=11) (B). (C, D) Relative SCL/TAL1 (C) and CD44 (D) expression in unsorted bone marrow cells of patients in chronic phase (CP) (circles), accelerated phase (AP) (squares) or blast crisis (BC) (triangles) of CML vs. normal human CD34+ cells (upside down triangles). Gene expression for each individual sample is normalized to mean expression in CP samples and is shown on a log10 scale. The expression of SCL/TAL1 in CP CML is significantly lower than that in human CD34+ cells from healthy individuals [P=0.042, analysis of variance (ANOVA); Tukey test]. (C) and the expres- sion of CD44 is significantly higher in BC than in CP CML (P<0.0001, ANOVA; Tukey test. CP, n=42; AP, n=17; BC, n=31; normal CD34+ cells, n=6) (D). (E) Negative correlation between SCL/TAL1 and CD44 expression in CD34+ sorted samples from CP CML patients (n=59) from the study by McWeeney et al.34 (P=0.002, correlation coefficient -0.40). Normalized log2-transformed expression is shown. (F, G) Kaplan-Meier-style curve of the probability of relapse (P=0.033, log-rank test) (F) or relapse-free survival (P=0.024, log-rank test) (G) of CP CML patients grouped by low or high expression of SCL/TAL1 (n=37).
haematologica | 2020; 105(1)
145